1-phenylchromeno[3,4-d]imidazol-4(1H)-one | 87236-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenylchromeno[3,4-d]imidazol-4(1H)-one
• 英文别名: 1-phenyl[1]benzopyrano[3,4-d]imidazol-4-(1H)-one；(1)BENZOPYRANO(3,4-d)IMIDAZOL-4(1H)-ONE, 1-PHENYL-；1-phenylchromeno[3,4-d]imidazol-4-one
• CAS: 87236-24-6
• 化学式: C₁₆H₁₀N₂O₂
• 分子量: 262.268
• InChiKey: XFCLFMIGIKTGFN-UHFFFAOYSA-N

物化性质

• 熔点：
  211-213 °C
• 沸点：
  500.6±19.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯-3-硝基香豆素 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 20.0~110.0 ℃ 、500.01 kPa 条件下， 反应 1.17h， 生成 1-phenylchromeno[3,4-d]imidazol-4(1H)-one
  参考文献：
  名称：

  10.24820/ark.5550190.p011.180dummy2

  摘要：

  DOI：

  10.24820/ark.5550190.p011.180dummy2

文献信息

• Simple and Efficient Copper(I)-Catalyzed Access to Three Versatile Aminocoumarin-Based Scaffolds using Isocyanoacetate
  作者：Tao Meng、Yiquan Zou、Oleg Khorev、Yu Jin、Huayong Zhou、Yongliang Zhang、Dingyu Hu、Lanping Ma、Xin Wang、Jingkang Shen

  DOI：10.1002/adsc.201000895

  日期：2011.4.18

  An efficient method has been developed for the one‐pot copper(I)‐catalyzed synthesis of 3‐aminocoumarin and its derivatives, such as 3‐substituted methylideneaminocoumarins and chromeno[3,4‐d]imidazol‐4(1H)‐ones. Significantly, the strategy presents a straightforward and efficient approach to constructing biologically useful molecular scaffolds.

  已开发出一种有效的方法，用于一锅铜（I）催化的3-氨基香豆素及其衍生物的合成，例如3-取代的亚甲基氨基香豆素和chromeno [3,4- d ]咪唑-4（1 H）-ones 。重要的是，该策略为构建生物学上有用的分子支架提供了一种简单有效的方法。
• Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
  申请人：OMEROS CORPORATION

  公开号：US20130267502A1

  公开（公告）日：2013-10-10

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开涉及使用磷酸二酯酶7（PDE7）抑制剂，单独或与其他治疗药物联合治疗成瘾和原发性冲动控制障碍。
• Use of PDE7 Inhibitors for the Treatment of Movement Disorders
  申请人：OMEROS CORPORATION

  公开号：US20140179717A1

  公开（公告）日：2014-06-26

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。该发明的一个方面是在给予多巴胺激动剂或前体（如左旋多巴）的同时给予PDE7抑制剂。在该发明的另一个方面，PDE7抑制剂可以相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病有效的药物作用的靶点而选择性地作用于PDE7。
• USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS
  申请人：Omeros Corporation

  公开号：US20160015715A1

  公开（公告）日：2016-01-21

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  本发明涉及一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。本发明的一个方面提供了与多巴胺激动剂或前体（例如左旋多巴）一起给予PDE7抑制剂的治疗方法。在本发明的另一个方面，PDE7抑制剂可以选择性地作用于PDE7，而相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病的药物作用的靶点。
• Treatment of addiction and impulse-control disorders using PDE7 inhibitors
  申请人：Omeros Corporation

  公开号：US11207275B2

  公开（公告）日：2021-12-28

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开内容涉及使用磷酸二酯酶 7 (PDE7) 抑制剂单独或与其他治疗剂联合治疗成瘾症和原发性冲动控制障碍。